Assessment of Psilocybin (TRP-8802) in Concert With Psychotherapy in Patients With Irritable Bowel Syndrome (IBS)

This looks modestly more likely than not to read out positively because the listed primary endpoint is immediate post-dose safety, not a high-bar efficacy comparison. The protocol excludes patients with exclusionary psychiatric or medical disorders, uses psychotherapy preparation and integration, and includes close monitoring around dosing, which should lower the chance of severe hypertension or severe abuse-related psychological events. The endpoint timing also helps: because the primary assessment is immediately after intervention, longer-term IBS heterogeneity, follow-up dropout, and the waitlist-control design are less important for whether the primary readout is acceptable. The main negatives are that psilocybin-based dosing can still trigger acute cardiovascular or psychiatric events, and the waitlist design is weaker for any broader efficacy narrative if safety is fine but symptom data are mixed. Operationally, the study is just past estimated primary completion and still listed active not recruiting, so results may be near, though reporting could lag. Overall, the endpoint structure and risk-mitigated population make YES a moderate favorite.

The primary endpoints are safety-focused (hypertension and abuse-related psychological events), which strongly favors positive results given psilocybin's well-established safety profile across 50+ FDA-registered studies. Interim data from the first 4 of up to 10 patients showed 75% reported clinically meaningful decreases in abdominal pain and anxiety. Prior TRP-8802 trials in fibromyalgia (5/5 patients improved) and BED (>80% episode reduction) were positive. However, significant uncertainties exist: the trial is very small (up to 10 patients), open-label, and the PI herself noted the approach 'has not worked for everyone.' The question of whether results are 'positive' is ambiguous — mixed efficacy signals in a safety-focused Phase 2a could be spun either way. The trial is 32 days past its estimated primary completion date with no final results announced yet. The small sponsor (micro-cap, ASX-listed) adds disclosure timing uncertainty. Balancing the favorable safety endpoint structure and encouraging interim signals against the mixed efficacy picture and ambiguity, I estimate ~62% YES probability.

This Phase 2 trial tests TRP-8802 (psilocybin) combined with psychotherapy for IBS using a randomized waitlist control design. The primary endpoints focus on safety: hypertension events (BP >200/110 for >15 min) and abuse-related psychological events (severe BPRS scores). These are adverse event incidence measures, not efficacy endpoints. The trial has passed its primary completion date (2026-03-01) and is now Active Not Recruiting. While the brief summary mentions collecting pain scores and stool data for efficacy assessment, the primary question centers on safety outcomes. Phase 2 safety trials typically have reasonable success rates if the compound shows acceptable tolerability in earlier studies. However, pschoactive psychedelics carry inherent psychological risks that could trigger the abuse-related psychological events endpoint. The waitlist design adds complexity as it measures sustained effects against control. Overall uncertainty is high given the novel indication (IBS with psilocybin) and dual safety endpoints. Market pricing near 50% reflects this uncertainty.

This Phase 2 trial assesses safety (primary endpoint) and exploratory efficacy for psilocybin in IBS. The primary endpoint is safety-focused, measuring severe hypertension and psychiatric adverse events, which is a low bar for a 'positive' result in the conventional sense. While the design is reasonable (randomized waitlist control), the indication is complex and the mechanism (psychedelic-assisted therapy for a gastrointestinal disorder) is novel and high-risk, with limited prior clinical precedent. The sponsor is a small-cap biotech (TRYP). The trial recently completed primary data collection (-32 days), but results are not yet disclosed. Given the endpoint's safety nature, the novel mechanism, and the sponsor's profile, the intrinsic odds of a clearly 'positive' outcome—likely defined as meeting both safety and suggestive efficacy signals—are below even.

Phase 2 randomized waitlist-controlled trial tests psilocybin (TRP-8802) + psychotherapy in IBS patients (all subtypes, no major psychiatric/medical exclusions), ideal for clean signal. Primary endpoints are rigorous safety metrics: hypertension incidence (>200 sys/>110 dia >15min, 4 readings) and severe psych events (BPRS hallucinations/psychosis/mood/cognition >=severe, scale 0-7). Psilocybin's safety is robust from 1000+ psychiatric trial exposures; severe HTN <1%, psych AEs transient/mild with therapy/support. Waitlist unblinds but irrelevant for acute post-dose safety. Efficacy secondaries (weekly worst pain avg, stool freq/consistency) are FDA-validated IBS endpoints, tracked to 12mo for durability. Novel IBS indication leverages gut-brain axis, serotonin modulation, prior psilocybin psych efficacy. Small specialist sponsor (TRYP) ensures protocol adherence (prep/integration). Overdue completion (-32d) but active status implies data ready, minimal disclosure risk. High likelihood primary safety met (low AE incidence), efficacy plausible upside.

The primary endpoints are safety-related (hypertensive events and psychiatric adverse events), not efficacy. A 'positive' result requires showing that these adverse events do not occur. While psilocybin is generally safe, the strict safety thresholds (e.g., BP > 200 systolic) in a potentially small Phase 2 trial leaves little margin for error. A single adverse event could cause the trial to fail its primary safety endpoints. Furthermore, the lack of an active control and the use of an open-label design may introduce bias, but the strict safety criteria make a 'positive' (safe) outcome uncertain. The indication (IBS) is also novel for psilocybin, adding risk. I estimate a 35% chance the trial meets its primary safety endpoints without significant issues.

This Phase 2 trial tests psilocybin for IBS, an unconventional indication with limited precedent. The primary endpoints are safety-focused (hypertension events, abuse-related psychological events) rather than efficacy, suggesting this is primarily a safety/signal-finding study. The design uses a waitlist control, which is weaker than placebo control for subjective outcomes like IBS symptoms. The trial completed enrollment 32 days ago but has extended follow-up to 12 months, meaning topline results may not be imminent. Psilocybin in IBS lacks robust mechanistic rationale or prior positive data. The safety endpoints are binary adverse event measures where 'positive' likely means no serious safety signals, but the question asks about 'results' generally, which could include efficacy. Given the exploratory nature, small sample size typical of Phase 2, and unvalidated indication, the probability of clearly positive results is below 50%.

The primary endpoints for this Phase 2a trial of TRP-8802 (oral psilocybin) in IBS are strictly safety-focused, measuring extreme adverse events—specifically blood pressure exceeding 200 systolic for over 15 minutes, and 'severe' psychological events on the BPRS scale. In a highly controlled clinical setting at Massachusetts General Hospital with rigorous screening, the incidence of these extreme adverse events is historically very rare for 25mg of psilocybin. Furthermore, the trial's sponsor (now Tryptamine Therapeutics) released highly encouraging interim data in December 2024, explicitly titling the press release 'Positive interim results.' The update confirmed that 4 of the up to 10 targeted patients had been successfully dosed, with 75% reporting a clinically meaningful reduction in abdominal pain and gastrointestinal anxiety. Strategically, the sponsor is using this pilot study to validate the IBS indication before advancing their proprietary IV-infused psilocin candidate (TRP-8803). Given their clear incentive to highlight the positive signal, the lack of severe safety events so far, and the explicitly positive interim framing, the final trial results are exceptionally likely to be reported as positive. The current market price of ~50% vastly underestimates the strength of the interim data and the high safety threshold.

The trial is a Phase 2 study assessing the efficacy of Psilocybin (TRP-8802) in combination with psychotherapy for patients with Irritable Bowel Syndrome (IBS). The study design involves a randomized waitlist control, which is a robust approach. The primary endpoints focus on the incidence of treatment-emergent adverse events and abuse-related psychological events, which are relevant for a drug under investigation. Given that the study is active and not recruiting, it implies that the initial phases have been completed successfully, suggesting a positive outlook. However, the small sample size and specific patient population may limit the generalizability of the results. Overall, the design and endpoints suggest a potentially positive outcome.